Examinando por Autor "De Sanctis, Juan B."
Mostrando 1 - 2 de 2
Resultados por página
Opciones de ordenación
Ítem Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy?(MDPI, 2021) Chávez-Castillo, Mervin; Ortega, Ángel; Cudris-Torres, Lorena; Duran, Pablo; Rojas, Milagros; Manzano, Alexander; Garrido, Bermary; Salazar, Juan; Silva, Aljadis; Rojas-Gomez, Diana Marcela; De Sanctis, Juan B.; Bermúdez, ValmoreChronic pain (CP) is a severe clinical entity with devastating physical and emotional consequences for patients, which can occur in a myriad of diseases. Often, conventional treatment approaches appear to be insufficient for its management. Moreover, considering the adverse effects of traditional analgesic treatments, specialized pro-resolving lipid mediators (SPMs) have emerged as a promising alternative for CP. These include various bioactive molecules such as resolvins, maresins, and protectins, derived from ω-3 polyunsaturated fatty acids (PUFAs); and lipoxins, produced from ω-6 PUFAs. Indeed, SPMs have been demonstrated to play a central role in the regulation and resolution of the inflammation associated with CP. Furthermore, these molecules can modulate neuroinflammation and thus inhibit central and peripheral sensitizations, as well as long-term potentiation, via immunomodulation and regulation of nociceptor activity and neuronal pathways. In this context, preclinical and clinical studies have evidenced that the use of SPMs is beneficial in CP-related disorders, including rheumatic diseases, migraine, neuropathies, and others. This review integrates current preclinical and clinical knowledge on the role of SPMs as a potential therapeutic tool for the management of patients with CP.Ítem The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises(MDPI, 2022) Ortega, Ángel; Vera, Ivana; Diaz, Maria P.; Navarro, Carla; Rojas, Milagros; Torres, Wheeler; Parra, Heliana; Salazar, Juan; De Sanctis, Juan B.; Bermúdez, ValmoreThe yes-associated protein (YAP) and the transcriptional coactivator with PDZ-binding motif (TAZ) are transcriptional coactivators, members of the Hippo signaling pathway, which play a critical role in cell growth regulation, embryonic development, regeneration, proliferation, and cancer origin and progression. The mechanism involves the nuclear binding of the un-phosphorylated YAP/TAZ complex to release the transcriptional enhanced associate domain (TEAD) from its repressors. The active ternary complex is responsible for the aforementioned biological effects. Overexpression of YAP/TAZ has been reported in cancer stem cells and tumor resistance. The resistance involves chemotherapy, targeted therapy, and immunotherapy. This review provides an overview of YAP/TAZ pathways’ role in carcinogenesis and tumor microenvironment. Potential therapeutic alternatives are also discussed.